Phil Taylor
LightNews LightNews
philbytaylor.bsky.social
Phil Taylor
@philbytaylor.bsky.social
50 followers 140 following 37 posts
Yazar ve gazeteciyim
Posts Replies Media Videos
philbytaylor.bsky.social
Think the #cricket may be wrapped up by the end of the day! #testmatch
July 4, 2025 at 10:21 AM
Reposted by Phil Taylor
pharmaphorum.bsky.social
Scientists behind a study suggesting #GSK's respiratory syncytial virus (#RSV) #vaccine could be protective against #dementia have said the #adjuvant used in the shot may be responsible.

pharmaphorum.com/news/could-v...
June 26, 2025 at 11:21 AM
Reposted by Phil Taylor
pharmaphorum.bsky.social
#NektarTherapeutics has said phase 2b results show it was right to keep faith with #rezpegaldesleukin as a therapy for #atopicdermatitis, also known as #eczema.
Nektar eyes pivotal trials for eczema drug cast off by Lilly
Nektar Therapeutics has said phase 2b results show it was right to keep faith with rezpegaldesleukin as a therapy for atopic dermatitis.
buff.ly
June 26, 2025 at 12:00 PM
Reposted by Phil Taylor
pharmaphorum.bsky.social
The #EuropeanCommission has approved #PTCTherapeutics' treatment for the rare disease phenylketonuria (#PKU), #Sephience, setting up a market debut in Germany next month.

pharmaphorum.com/news/germany...
Germany will be first launch for PTC's phenylketonuria drug
PTC Therapeutics' treatment for the rare disease PKU, Sephience, will launch in its first market next month after getting EU approval.
pharmaphorum.com
June 25, 2025 at 11:05 AM
Reposted by Phil Taylor
pharmaphorum.bsky.social
A #genetherapy for #Fabrydisease could be on the horizon, after a clinical trial readout for #SangamoTherapeutics' ST-920 hit its safety and efficacy endpoints.

buff.ly/A51kdwd
June 25, 2025 at 12:00 PM
Reposted by Phil Taylor
pharmaphorum.bsky.social
Millions of children around the world are at risk of serious #infectiousdiseases because #immunisation programmes have stalled, or even gone into reverse, in the last 20 years.
Alarm as study finds global vaccination coverage stalls
Millions of children around the world are being left at risk of serious infectious diseases because immunisation programmes have stalled, says study.
buff.ly
June 25, 2025 at 1:01 PM
Reposted by Phil Taylor
securingindustry.bsky.social
What's behind a spike in illicit tobacco use in Europe?
#illicittrade

www.securingindustry.com/what-s-behin...
What's behind a spike in illicit tobacco use in Europe?
Smokers in the EU consumed 38.9bn illicit cigarettes in 2024, a 10.8% increase on the prior year attributed to tax rises.
www.securingindustry.com
June 23, 2025 at 2:33 PM
Reposted by Phil Taylor
pharmaphorum.bsky.social
#Roche's #Hemlibra treatment for #haemophiliaA is one of its top-selling drugs, making almost $5 billion last year, and the company has now lined up what looks like an impressive successor.
Roche's Hemlibra follow-up set for phase 3 in haemophilia A
Roche has positive data with its follow-up to haemophilia A blockbuster Hemlibra, but a rival drug from Novo Nordisk is looming.
buff.ly
June 23, 2025 at 1:00 PM
Reposted by Phil Taylor
pharmaphorum.bsky.social
In response to the #IRA and the #EO and their potential impact on revenues, #pharmaceuticalcompanies are exploring various strategies.

pharmaphorum.com/sales-market...
US drug pricing overhaul: The Inflation Reduction Act (IRA) and the Executive Order (EO) on Most-Favored-Nation (MFN) drug pricing in focus
Together, these policies signal a new era of pricing accountability and regulatory oversight, with significant implications for drug development strategies, market access, and patient affordability.
pharmaphorum.com
June 23, 2025 at 12:19 PM
Reposted by Phil Taylor
pharmaphorum.bsky.social
A first look at the phase 3 data with #EliLilly's oral #GLP1 agonist #orforglipron reveals encouraging blood sugar control data in patients with #type2diabetes, and a side-effect profile free of the liver toxicity that scuppered rival candidates from Pfizer. #ADA25

pharmaphorum.com/news/ada-lil...
ADA: Lilly makes its case for oral GLP-1 orforglipron
Lilly is on track to file its oral GLP-1 agonist orforglipron for type 2 diabetes next year after presenting the first phase 3 data with the drug.
pharmaphorum.com
June 23, 2025 at 12:02 PM
Reposted by Phil Taylor
pharmaphorum.bsky.social
#NovoNordisk has reported new data from its phase 3 programme for weight-loss therapy #CagriSema, trying to restore confidence in the drug after earlier readouts disappointed investors. #ADA

pharmaphorum.com/news/ada-nov...
June 23, 2025 at 10:08 AM
Reposted by Phil Taylor
pharmaphorum.bsky.social
#MadrigalPharma could be just weeks away from becoming the first drugmaker to claim #EU approval for a treatment for metabolic dysfunction-associated steatohepatitis (#MASH).
Madrigal closes on EU approval of first MASH treatment
Madrigal Pharma could be just weeks away from becoming the first drugmaker to claim EU approval for a MASH treatment.
buff.ly
June 20, 2025 at 3:30 PM
Reposted by Phil Taylor
pharmaphorum.bsky.social
NEWS: For the second year running, data at ASCO on Merus' bispecific antibody petosemtamab in head and neck cancer has drawn the eye.

pharmaphorum.com/news/asco-25...
ASCO 25: Merus bispecific scores again in HNSCC
For the second year running, data at ASCO on Merus' bispecific antibody petosemtamab in head and neck cancer has drawn the eye
pharmaphorum.com
May 27, 2025 at 1:03 PM
Reposted by Phil Taylor
pharmaphorum.bsky.social
NEWS: Despite a voluntary admission of a breach of the ABPI code, Sanofi is deemed to have "brought discredit" on the pharma industry.

pharmaphorum.com/news/sanofi-...
Sanofi admits giving free Olympics tickets to patients
Despite a voluntary admission of a breach of the ABPI code, Sanofi is deemed to have "brought discredit" on the pharma industry
pharmaphorum.com
May 27, 2025 at 10:34 AM
Reposted by Phil Taylor
pharmaphorum.bsky.social
NEWS: Find out what medicines got a go-ahead from the CHMP at its May meeting, and which were turned down.

pharmaphorum.com/news/autolus...
May 27, 2025 at 9:57 AM
Reposted by Phil Taylor
pharmaphorum.bsky.social
NEWS: Hopes rise for an end to a 50-year drought in new antibiotics for a top priority 'superbug', as Roche moves a candidate into phase 3.

pharmaphorum.com/news/roche-t...
Roche takes new antibiotic into phase 3 for 'urgent threat'
Roche is moving its antibiotic zosurabalpin into phase 3 for CRAB, potentially a big step forward in the fight against antimicrobial resistance
pharmaphorum.com
May 27, 2025 at 8:49 AM
Reposted by Phil Taylor
pharmaphorum.bsky.social
We need to broaden access to #advancedtechnologies so that, ultimately, every #patient can benefit from them. It’s a goal otherwise referred to as the “hyperscaling of #healthcare”. #AI
Hyperscaling healthcare with data science
We need to broaden access to advanced technologies so that, ultimately, every patient can benefit from them. It’s a goal otherwise known as the “hyperscaling of healthcare”.
buff.ly
May 27, 2025 at 8:30 AM
Reposted by Phil Taylor
pharmaphorum.bsky.social
April was a big month for healthcare #investors, as three firms named new directors. Catch up with the #agency, #consultancy, and investor #hires from April in a new #ChangingFaces.

pharmaphorum.com/sales-market...
Changing Faces – Agency, consultancy, and investor hires – April 2025
Stay up-to-date with the agency, consultancy, and investor hires from April.
pharmaphorum.com
May 27, 2025 at 7:04 AM
Reposted by Phil Taylor
pharmaphorum.bsky.social
NEWS: Roche kicks off this year's ASCO with strong data in breast cancer.

pharmaphorum.com/news/asco-25...
ASCO 25: Roche places Itovebi marker in breast cancer
Roche's Itovebi has become the first PI3K inhibitor to extend survival in HR-positive, HER2-negative breast cancer with a PIK3CA mutation
pharmaphorum.com
May 23, 2025 at 1:29 PM
Reposted by Phil Taylor
pharmaphorum.bsky.social
NEWS: Alzheimer's Association has hit out at "inaccurate and dangerous fabrications" by HHS Secretary RFK Jr about NIH dementia research.

pharmaphorum.com/news/rfk-jr-...
May 23, 2025 at 12:46 PM
Reposted by Phil Taylor
pharmaphorum.bsky.social
NEWS: There's a new treatment on the way for people living with rare kidney disease IgAN in the UK.

pharmaphorum.com/news/nice-re...
NICE relents and backs drug for IgAN from CSL Vifor
Thousands of people living with rare kidney disease IgAN in the UK will soon be able to access a new oral treatment from CSL Vifor
pharmaphorum.com
May 23, 2025 at 10:31 AM
Reposted by Phil Taylor
pharmaphorum.bsky.social
NEWS: There's a second biologic approved for COPD, increasing the options for patients with the serious respiratory disease.

pharmaphorum.com/news/gsk-cla...
GSK claims first approval for Nucala in COPD
GSK gets FDA approval for Nucala in COPD, setting up a marketing tussle with Sanofi/Regeneron's Dupixent
pharmaphorum.com
May 23, 2025 at 10:09 AM
Reposted by Phil Taylor
pharmaphorum.bsky.social
NEWS: Does Hinge Health's successful IPO signal a return to favour for digital health stocks? pharmaphorum.com/news/digital...
Digital player Hinge Health rises sharply after NYSE debut
In a signal of a return to investor appetite for digital health stocks, Hinge Health has raised an impressive $437 million in an IPO
pharmaphorum.com
May 23, 2025 at 9:55 AM
Reposted by Phil Taylor
securingindustry.bsky.social
Switzerland makes it easier to destroy #counterfeit goods url:https://www.securingindustry.com/switzerland-makes-it-easier-to-destroy-counterfeit-goods/s112/a16989/
May 22, 2025 at 2:16 PM
Reposted by Phil Taylor
securingindustry.bsky.social
New IACC council seeks #counterfeit free online marketplace
www.securingindustry.com/iacc-council...
IACC council seeks 'counterfeit-free online marketplace'
The MAC wants to foster collaboration between online marketplaces, payment providers, and brands to fight counterfeits.
www.securingindustry.com
May 21, 2025 at 2:35 PM